Premium
Chronic drug‐induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell‐derived cardiomyocytes
Author(s) -
Kopljar Ivan,
De Bondt An,
Vinken Petra,
Teisman Ard,
Damiano Bruce,
Goeminne Nick,
Van den Wyngaert Ilse,
Gallacher David J,
Lu Hua Rong
Publication year - 2017
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13713
Subject(s) - cardiotoxicity , medicine , induced pluripotent stem cell , troponin i , drug , pharmacology , troponin , arsenic trioxide , heart failure , toxicity , cardiology , apoptosis , chemistry , myocardial infarction , biochemistry , embryonic stem cell , gene
In the pharmaceutical industry risk assessments of chronic cardiac safety liabilities are mostly performed during late stages of preclinical drug development using in vivo animal models. Here, we explored the potential of human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) to detect chronic cardiac risks such as drug-induced cardiomyocyte toxicity.